Nyxoah shares back above their €0.73 support and rebound
The Belgian specialist in sleep apnea implants rebounded intraday, after a quarterly publication released on November 5 confirmed the ramp-up of its US market. The move is part of a long phase of decline, which leaves the stock well below its levels of last year.
A rebound that recovers only a small part of the quarterly decline
Nyxoah shares gain 3.45% to €0.78 at midday, after closing at €0.75. This gain barely offsets the 38.49% decline recorded over three months, to which is added a drop of nearly 82% over one year.
On Friday, the stock had broken its €0.73 support intraday before climbing back above it. It now trades below its three moving averages: the MA20 at €0.86 is 9.3% above the price, and the MA50 at €1.13 is much higher. The RSI at 34 reflects a still-selling momentum, but close to the oversold zone.
US sales up, revenue forecast lowered
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
On November 5, the group reported third-quarter revenue of €9.2 million, up 19% on the second quarter. US sales rose 29% to €6.7 million. However, the company had already lowered its 2026 forecast on October 19: it is now between €33 million and €35 million.
On the analyst side, Invest Securities maintained its buy rating today with a price target of €3.00, nearly four times the current price. This target contrasts with a stock trading below €1, whose €0.73 support is the nearest reference point.
Related
SectorDispositifs médicaux et optique›Dispositifs médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 23,2 millions d'euros
Quarterly revenue: 23,2 millions d'euros
Revenue growth: 430,6 %
Net income: -66,7 millions d'euros
Guidance from the release
« The Company expects global net revenue for the full year 2026 to be in the range of €33 million to €35 million. »
Outlook / guidance
Expected revenue: 34 millions d'euros
Management commentary: « The Company expects global net revenue for the full year 2026 to be in the range of €33 million to €35 million. »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
